Overview: Amphetamine Screen TestIntroduction: The Amphetamine Screen Test detects amphetamine use, which may indicate substance abuse causing restlessness, heart palpitations, or behavioral changes. Aligned with 2023 SAMHSA guidelines, it uses chromatography for high sensitivity, aiding in drug screening. This test is critical for guiding treatment, monitoring substance use, and improving outcomes in toxicology for patients with suspected drug abuse.
Other Names: Amphetamine Assay, Drug Screen for Amphetamines.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Drug screening began in the 1970s with immunoassays. Chromatography for amphetamines emerged in the 1990s, and by the 2000s, mass spectrometry improved specificity.
Purpose: Detects amphetamine use, guides substance abuse treatment, and monitors compliance in patients with symptoms like restlessness or palpitations.
Test Parameters: 1. Amphetamine
Pretest Condition: No fasting required. Collect urine, serum, or plasma at any time. Report symptoms like restlessness or behavioral changes, and list medications like ADHD drugs.
Specimen: 5-20 mL urine (sterile container), 2-5 mL serum (SST), or 2-4 mL plasma (EDTA). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document symptoms, drug use history, or family history of substance abuse. Include current medications, especially amphetamines or antidepressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for treatment or counseling.
Procedural Considerations: Uses chromatography (e.g., gas chromatography-mass spectrometry) to detect amphetamines. Results are available in 1-2 days, supporting rapid decisions.
Factors Affecting Result Accuracy: Cross-reactivity with medications like pseudoephedrine may cause false positives. Improper storage can degrade samples.
Clinical Significance: Positive results confirm amphetamine use, prompting treatment or counseling. Negative results may require confirmatory testing with mass spectrometry.
Specialist Consultation: Consult a toxicologist or addiction specialist for result interpretation. A counselor referral is advised for substance abuse management.
Additional Supporting Tests: Confirmatory mass spectrometry, urine drug panel, or blood toxicology to confirm amphetamine use or detect other substances.
Test Limitations: False positives may occur with certain medications. Testing may miss recent or low-level use, requiring clinical correlation.
References: SAMHSA Drug Testing Guidelines, 2023; Journal of Analytical Toxicology, Cone EJ, 2022.
